These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 25447595)
1. Tranilast: a review of its therapeutic applications. Darakhshan S; Pour AB Pharmacol Res; 2015 Jan; 91():15-28. PubMed ID: 25447595 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Rogosnitzky M; Danks R; Kardash E Anticancer Res; 2012 Jul; 32(7):2471-8. PubMed ID: 22753703 [TBL] [Abstract][Full Text] [Related]
3. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789 [TBL] [Abstract][Full Text] [Related]
4. Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Yamamoto M; Yamauchi T; Okano K; Takahashi M; Watabe S; Yamamoto Y Tohoku J Exp Med; 2009 Mar; 217(3):193-201. PubMed ID: 19282654 [TBL] [Abstract][Full Text] [Related]
5. Anti-cancer effects of Tranilast: An update. Osman S; Raza A; Al-Zaidan L; Inchakalody VP; Merhi M; Prabhu KS; Abdelaziz N; Hydrose S; Uddin S; Dermime S Biomed Pharmacother; 2021 Sep; 141():111844. PubMed ID: 34174504 [TBL] [Abstract][Full Text] [Related]
6. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Platten M; Wild-Bode C; Wick W; Leitlein J; Dichgans J; Weller M Int J Cancer; 2001 Jul; 93(1):53-61. PubMed ID: 11391621 [TBL] [Abstract][Full Text] [Related]
7. Tranilast inhibits the cell growth of normal human keratinocytes in vitro. Kubo M; Zhao Y; Moriguchi T Arch Dermatol Res; 2012 Nov; 304(9):745-53. PubMed ID: 23053220 [TBL] [Abstract][Full Text] [Related]
8. Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit. Massoud G; Parish M; Hazimeh D; Moukarzel P; Singh B; Cayton Vaught KC; Segars J; Islam MS Int Immunopharmacol; 2024 Aug; 137():112423. PubMed ID: 38861914 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis. Kondo N; Fukutomi O; Shinbara M; Orii T Biotherapy; 1994; 8(1):19-22. PubMed ID: 7547077 [TBL] [Abstract][Full Text] [Related]
10. Tranilast Inhibits Genes Functionally Involved in Cell Proliferation, Fibrosis, and Epigenetic Regulation and Epigenetically Induces miR-29c Expression in Leiomyoma Cells. Chuang TD; Khorram O Reprod Sci; 2017 Sep; 24(9):1253-1263. PubMed ID: 28114878 [TBL] [Abstract][Full Text] [Related]
11. Effect of tranilast on matrix metalloproteinase-1 secretion from human gingival fibroblasts in vitro. Maita E; Sato M; Yamaki K J Periodontol; 2004 Aug; 75(8):1054-60. PubMed ID: 15455731 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids. Chuang TD; Munoz L; Quintanilla D; Boos D; Khorram O Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445642 [TBL] [Abstract][Full Text] [Related]
13. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Bonnet F; Cao Z; Cooper ME; Cox AJ; Kelly DJ; Gilbert RE Diabetes Metab; 2003 Sep; 29(4 Pt 1):386-92. PubMed ID: 14526266 [TBL] [Abstract][Full Text] [Related]
14. The Effect of Tranilast 8% Liposomal Gel Versus Placebo on Post-Cesarean Surgical Scars: A Prospective Double-Blind Split-Scar Study. Kohavi L; Sprecher E; Zur E; Artzi O Dermatol Surg; 2017 Sep; 43(9):1157-1163. PubMed ID: 28825957 [TBL] [Abstract][Full Text] [Related]
16. Suppression of matrix metalloproteinase production in nasal fibroblasts by tranilast, an antiallergic agent, in vitro. Shimizu T; Kanai K; Asano K; Hisamitsu T; Suzaki H Mediators Inflamm; 2005 Aug; 2005(3):150-9. PubMed ID: 16106101 [TBL] [Abstract][Full Text] [Related]
17. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Koyama S; Takagi H; Otani A; Suzuma K; Nishimura K; Honda Y Br J Pharmacol; 1999 May; 127(2):537-45. PubMed ID: 10385256 [TBL] [Abstract][Full Text] [Related]
18. Suppression of atherosclerotic development in Watanabe heritable hyperlipidemic rabbits treated with an oral antiallergic drug, tranilast. Matsumura T; Kugiyama K; Sugiyama S; Ota Y; Doi H; Ogata N; Oka H; Yasue H Circulation; 1999 Feb; 99(7):919-24. PubMed ID: 10027816 [TBL] [Abstract][Full Text] [Related]